THD NewsDesk, New Delhi: According to real world data, as published by the pharma company, Pfizer-BioNtech’s Covid-19 vaccine offers at least 97 per cent effectiveness in symptomatic Covid-19 cases.
Vaccine provides effectiveness against 94 per cent against asymptomatic SARS-CoV-2 infections as per the analysis based on real world data gathered by the Israel Ministry of Health. “As demonstrated in our Phase 3 clinical trial, we are extremely encouraged to announce that the real-world effectiveness data coming from Israel are confirming the high efficacy and showing the significant impact of inorder to prevent severe disease and deaths due to Covid-19” said Luis Jodar, Senior Vice President and Pfizer Vaccines, Chief Medical Officer said in a statement.
To monitor the real-world impact of the Pfizer-BioNTech Covid-19 vaccine, Pfizer and the Israel MoH entered into a collaboration agreement in January.
This comprehensive real-world evidence can be of importance to countries around the world as they advance their own vaccination campaigns one year after the World Health Organization (WHO) declared Covid-19 a pandemic.
For all outcomes, vaccine effectiveness was measured from two weeks after the second dose. The findings from the analysis were derived from de-identified aggregate Israel MoH surveillance data collected between January 17 and March 6, 2021.
